Bolt Biotherapeutics (NASDAQ:BOLT) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) shares passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $4.20 and traded as high as $4.48. Bolt Biotherapeutics shares last traded at $4.14, with a volume of 34,467 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bolt Biotherapeutics currently has a consensus rating of “Hold” and an average target price of $14.50.

Bolt Biotherapeutics Stock Performance

The firm has a market cap of $12.10 million, a price-to-earnings ratio of -0.38 and a beta of 1.00. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 1.47. The stock’s 50 day moving average is $3.77 and its 200 day moving average is $4.20.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($4.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.39) by ($1.18). Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.50 million. Analysts anticipate that Bolt Biotherapeutics, Inc. will post -11.10 earnings per share for the current year.

Insider Buying and Selling at Bolt Biotherapeutics

In related news, CEO William Quinn sold 9,132 shares of Bolt Biotherapeutics stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $3.24, for a total transaction of $29,587.68. Following the completion of the sale, the chief executive officer directly owned 25,384 shares of the company’s stock, valued at approximately $82,244.16. This trade represents a 26.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 38,584 shares of company stock worth $128,361 in the last 90 days. 9.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bolt Biotherapeutics stock. Nan Fung Group Holdings Ltd bought a new position in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 5,000 shares of the company’s stock, valued at approximately $19,250. Bolt Biotherapeutics makes up about 0.0% of Nan Fung Group Holdings Ltd’s holdings, making the stock its 25th biggest position. Nan Fung Group Holdings Ltd owned about 0.26% of Bolt Biotherapeutics as of its most recent SEC filing. 86.70% of the stock is owned by institutional investors and hedge funds.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is based on its Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, which is designed to combine the tumor-targeting ability of antibodies with agents that activate the innate immune system.

Bolt’s approach is intended to recruit and stimulate immune cells within the tumor microenvironment, potentially helping the body recognize and attack cancer cells.